SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form PRE 14A - Other preliminary proxy statements:
SEC Accession No. 0001104659-21-082753
Filing Date
2021-06-21
Accepted
2021-06-17 18:13:55
Documents
5
Period of Report
2021-07-28

Document Format Files

Seq Description Document Type Size
1 PRE 14A tm2119969-1_pre14a.htm PRE 14A 1341340
2 GRAPHIC lg_nabrivanew-4c.jpg GRAPHIC 81002
3 GRAPHIC sg_danburgess-bwg.jpg GRAPHIC 24004
4 GRAPHIC tm2119969d1_proxypg1-4c.jpg GRAPHIC 1585528
5 GRAPHIC tm2119969d1_proxypg2-4c.jpg GRAPHIC 947506
  Complete submission text file 0001104659-21-082753.txt   4972395
Mailing Address 1000 CONTINENTAL DRIVE SUITE 600 KING OF PRUSSIA PA 19406
Business Address 56 FITZWILLIAM SQUARE DUBLIN L2 2 (610) 816-6640
Nabriva Therapeutics plc (Filer) CIK: 0001641640 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L2 | Fiscal Year End: 1231
Type: PRE 14A | Act: 34 | File No.: 001-37558 | Film No.: 211026242
SIC: 2834 Pharmaceutical Preparations